Search for a trial

A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST-LINE METASTATIC COLORECTAL CANCER (MODUL)

EFFICACY OBJECTIVESWithin each cohort, the study has the following co-primary efficacy objectives:· Assessing early efficacy during the Maintenance Treatment Phase based on a 20%reduction in tumour size after 2 months of treatment· Evaluating PFSThe…

A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Naive Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

The primary objective of this trial is to determine if EMD 1201081 (formerly known as IMO-2055) has anti-tumor activity in subjects by examining its effects on accepted clinical endpoints in combination with cetuximab. • To evaluate progression-free…

Phase II study of Cetuximab combined with Cisplatin or Carboplatin/Pemetrexed as first line treatment in patients with malignant pleural mesothelioma

By adding Cetuximab to standard treatment, we hope to prolonge progression free survival

Bioimmunoradiotherapy (BIR) with concurrent Avelumab, Cetuximab and Radiotherapy as first line treatment in patients with locally advanced squamous cell carcinoma of the head and neck. A feasibility study in patients unfit for cisplatin

Feasibility

Image guided surgery for margin assessment of cutaneous squamous cell carcinoma during surgery: a phase I proof of concept study

The main purpose of this pilot study is to investigate the feasibility of fluorescence imaging using cetuximab-IRDye800CW for intraoperative margin assessment in patients with cutaneous squamous cell carcinoma.

An Open-label, Multicenter, Randomized Phase 3 Study of First line Encorafenib Plus Cetuximab With or Without Chemotherapy Agents versus Standard of Care Therapy with a Safety Lead-in of Encorafenib and Cetuximab Plus Chemotherapy In Participants with Metastatic BRAF V600E Mutant Colorectal Cancer

This study has been transitioned to CTIS with ID 2023-509405-77-00 check the CTIS register for the current data. The purpose of this Safety Lead In study is to explore if encorafenib and cetuximab in combination with a chemotherapy regimen (either…

Real-time margin assessment in head and neck cancer - enhancing specificity by combining fresh frozen sectioning with targeted fluorescence imaging
The LIGHTNING study

The main aim is to test whether cetuximab-IRDye800CW is a reliable marker for residual tumor remnants in resection margins after surgical removal of head and neck cancer. To increase the specificity of cetuximab-800CW, a specific frozen section can…

Fluorescent Guided Surgery in Penile Carcinoma using Cetuximab-800CW

The purpose of the current study is to determine the feasibility of using MFGS using Cetuximab-800CW as an intraoperative margin assessment tool for penile carcinoma.

Phase II single arm study of afatinib in combination with cetuximab in EGFR exon 20 insertion positive non-small-cell lung cancer

• To determine the disease control rate at 18 weeks of afatinib and cetuximab treatment in patients with NSCLC harboring an EGFR exon 20 insertion mutation. • To assess anti-tumor activity of afatinib and cetuximab in NSCLC patients harboring an…